Brainstorm Cell Therapeutics Files 8-K

TL;DR

Brainstorm Cell Therapeutics signed a material definitive agreement, filing an 8-K on April 2, 2024.

AI Summary

On April 2, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, but specific details of the agreement or financial figures were not immediately available in the provided text.

Why It Matters

This filing indicates a significant new agreement for Brainstorm Cell Therapeutics, which could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing of a material definitive agreement suggests a significant event, but the lack of specific details in the provided text makes it difficult to assess the immediate risk.

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
• April 2, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
• $100.0 million — ng an aggregate offering price of up to $100.0 million from time to time through an "at-the-ma

Filing Documents

• tm2410454d1_8k.htm (8-K) — 25KB
• tm2410454d1_ex1-1.htm (EX-1.1) — 20KB
• 0001104659-24-042513.txt ( ) — 219KB
• bcli-20240402.xsd (EX-101.SCH) — 3KB
• bcli-20240402_lab.xml (EX-101.LAB) — 33KB
• bcli-20240402_pre.xml (EX-101.PRE) — 22KB
• tm2410454d1_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, Brainstorm Cell Therapeutics Inc. (the "Company") entered into a distribution agreement (the "Distribution Agreement"), dated August 9, 2021, with Leerink Partners LLC ("Leerink Partners") and Raymond James & Associates, Inc. ("Raymond James") to sell shares of its common stock, par value $0.00005 per share (the "Common Stock"), having an aggregate offering price of up to $100.0 million from time to time through an "at-the-market" equity offering program under which Leerink Partners and Raymond James act as the Company's agents . On April 2, 2024, the Company entered into an amendment No. 1 to the Distribution Agreement ("Amendment No. 1") pursuant to which Leerink Partners ceased to be an agent under the Distribution Agreement. The foregoing description of the terms of the Amendment No. 1 does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment No. 1, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Amendment No. 1 dated April 2, 2024 to the Distribution Agreement dated August 9, 2024 by and among Brainstorm Cell Therapeutics Inc., Leerink Partners LLC and Raymond James & Associates, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: April 2, 2024 By: /s/ Chaim Lebovits Chaim Lebovits President and Co-Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR